2025-05-20-Jefferies-艾索基因（AXGN）_虚拟炉边谈话基本面依然强劲；预期毛利率反弹_7页_104kb

USA Medical Supplies & Devices | Equity Research | AxoGen
Date: May 20, 2025

Flash Note:

• Current Price: $11.57
• Rating: BUY
• New Price Target: $24.00 (+107% from current price)
• Catalyst: Positive FDA feedback, progress on Avance BLA filing, strong growth runway, transparency in guidance.

Summary:

1. Regulatory & Commercial Update: AxoGen reaffirms management's message from the Q1 earnings call, highlighting strong underlying fundamentals with broad-based market growth potential. The company remains confident in the progress of the Avance BLA application (scheduled PDUFA date: September). Key areas focus on commercial organization building, including sales force expansion to target 20 new reps by YE25.

2. Financials & Growth: Q1 guided growth was largely broad-based. While GM dipped due to process mix shifts at the Dayton facility and write-offs, management expects FY25 GM targets of 73-75%. Q2 GM improvement is expected. Long-term GM trajectory points towards 75%. Sales force expansion (doubling breast reps, adding extremity reps) is a key driver. Quarterly cadence normalized compared to 2024's holiday-boosted period.

3. Product: AxoGen develops an off-the-shelf nerve allograft product (Avance Nerve Graft) for peripheral nerve repair. The company stated its product adoption and market penetration levels provide a long growth runway (OMF/head & neck, breast resensation, extremities). AXGN INC. got its official symbol prior to market listing.

4. Valuation & Risks: Jefferies sets a $526M market cap and a $24 PT (2026E sales: 4x EV/sales). Risks include slower product adoption, regulatory delays for Avance, COVID disruptions, potential commercial disruption from new strategic plans, and competition.

**Disclaimer:** This is based on the *Recent Equity Research Report Flash Note* (dated May 20, 2025). It reflects the views of the analytical team mentioned. The report includes standard disclosures and analyst certification details typical for research reports, including qualifications and potential conflicts of interest.